Covid-19 roundup: Alnylam, Vir quietly deprioritize Covid-19 drug; Data suggest AstraZeneca's vaccine is only 10.4% effective against new variant
Vir Biotechnology’s biggest Covid-19 effort has been their monoclonal antibody, a bid they say has since proven effective, but it isn’t their only effort …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
